Immunology Preclinical Deal Benchmarks — China (2026)
Median upfront of $9M with total deal values reaching $194M in China territory.
Median Upfront
$9M
Total Deal Value
$125M
Royalty Range
3%–6.1%
Territory Multiplier
0.12x
Understanding Immunology Deal Benchmarks at Preclinical
Preclinical Immunology licensing deals in China territory command a median upfront payment of $9M, with values ranging from $3M at the low end to $15M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the immunology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $56M to $194M, with a median of $125M. Royalty rates for immunology assets at this stage typically fall between 3% and 6.1% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The China territory applies a 0.12x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating china rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $3M | $9M | $15M |
| Total Deal Value | $56M | $125M | $194M |
| Royalty Rate | 3% | — | 6.1% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Pharming Group | CSPC Pharmaceutical | $15M | $180M | licensing |
See All Comparable Deals
View 1 comparable Immunology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Immunology deals in China territory?
How does China territory affect Immunology deal value?
What royalty rates are typical for Preclinical Immunology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$20M upfront
Immunology · Phase 1 · China
$66M upfront
Immunology · Phase 2 · China
$108M upfront
Immunology · Phase 3 · China
$410M upfront
Immunology · Approved · China
$4M upfront
Oncology · Preclinical · China
$4M upfront
Neurology/CNS · Preclinical · China
$9M upfront
Metabolic/Obesity · Preclinical · China
$72M upfront
Immunology · Preclinical · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Immunology Preclinical Deal Benchmarks — China (2026). Retrieved from https://solidus.ambrosiaventures.co/data/immunology-preclinical-deals-china
<a href="https://solidus.ambrosiaventures.co/data/immunology-preclinical-deals-china">Immunology Preclinical Deal Benchmarks — China (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=immunology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.